Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Unicycive Therapeutics stock (Unicycive Therapeutics)

Buy Unicycive Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Unicycive Therapeutics is a biotechnology business based in the US. Unicycive Therapeutics shares (UNCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.48 – a decrease of 3.51% over the previous week. Unicycive Therapeutics employs 14 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Unicycive Therapeutics stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

How to buy Unicycive Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – UNCY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Unicycive Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Unicycive Therapeutics stock price (NASDAQ: UNCY)

Use our graph to track the performance of UNCY stocks over time.

Unicycive Therapeutics shares at a glance

Information last updated 2024-11-08.
Latest market close$0.48
52-week range$0.20 - $1.82
50-day moving average $0.41
200-day moving average $0.80
Wall St. target price$5.25
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.36

Is it a good time to buy Unicycive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Unicycive Therapeutics price performance over time

Historical closes compared with the close of $0.5332 from 2024-11-11

1 week (2024-11-06) 6.22%
1 month (2024-10-11) 44.11%
3 months (2024-08-13) 125.93%
6 months (2024-05-13) -51.08%
1 year (2023-11-13) -1.26%
2 years (2022-11-11) -25.43%
3 years (2021-11-12) 2.71
5 years (2019-11-10) N/A

Unicycive Therapeutics financials

Gross profit TTM $0
Return on assets TTM -53.37%
Return on equity TTM -121.76%
Profit margin 0%
Book value $-0.34
Market Capitalization $53.8 million

TTM: trailing 12 months

Unicycive Therapeutics share dividends

We're not expecting Unicycive Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Unicycive Therapeutics share price volatility

Over the last 12 months, Unicycive Therapeutics's shares have ranged in value from as little as $0.202 up to $1.818. A popular way to gauge a stock's volatility is its "beta".

UNCY.US volatility(beta: 2.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unicycive Therapeutics's is 2.286. This would suggest that Unicycive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Unicycive Therapeutics's beta into context you can compare it against those of similar companies.

Unicycive Therapeutics overview

Unicycive Therapeutics, Inc. , a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd. ; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd.

Frequently asked questions

What percentage of Unicycive Therapeutics is owned by insiders or institutions?
Currently 6.734% of Unicycive Therapeutics shares are held by insiders and 37.729% by institutions.
How many people work for Unicycive Therapeutics?
Latest data suggests 14 work at Unicycive Therapeutics.
When does the fiscal year end for Unicycive Therapeutics?
Unicycive Therapeutics's fiscal year ends in December.
Where is Unicycive Therapeutics based?
Unicycive Therapeutics's address is: 4300 El Camino Real, Los Altos, CA, United States, 94022
What is Unicycive Therapeutics's ISIN number?
Unicycive Therapeutics's international securities identification number is: US90466Y1038

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site